Our oral biotherapies are based on single-strain keystone bacteria. They aim to restore the missing functions of the gut microbiome to treat at a clinically relevant level life impacting diseases.

Efficacy-driven drug candidate selection paired with rapid clinical development are the two pillars of our unique therapeutic platform.

Lab facilities

200m2 | 10 higly skilled people (PhD, PhD students, PharmD, Engineers, Engineers assistants)

Microbiome & us
News
Apr 8, 2022
YSOPIA Bioscience Announces the Appointment of Dr. Jean-Pierre Lehner as New Chairman of the Board of Directors |...
> more
Apr 8, 2022
YSOPIA Bioscience annonce la nomination du Dr. Jean-Pierre Lehner comme nouveau Président du Conseil d’Administration...
> more
Press / Media
Apr 14, 2022
     Fabrice Guez, CEO et CFO d’Ysopia Bioscience Observation au microscope de la morphologie de bactéries...
> more
Mar 15, 2022
Le fonds Health for Life Capital II™ et les sociétés de son portefeuille ont connu une année 2021 exceptionnelle....
> more
Publications
Apr 11, 2022
Karima Relizani, Katy Le Corf, Camille Kropp, Rebeca Martin-Rosique, Déborah Kissi, Guillaume Déjean, Lisa...
> more
Feb 16, 2022
Samuel Bellais, Mélanie Nehlich, Maryne Ania, Aurore Duquenoy, Wilfrid Mazier, Ger van den Engh, Jan Baijer, Nicole...
> more
now on twitter
YSOPIA Bioscience

Antimicrobial resistant bacteria are present in newborns after just a few hours of life and they help to understand… t.co/jkL4ih4dFA

YSOPIA Bioscience © 2022 - all rights reserved terms and conditions